OTCMKTS:OREXQ

Orexigen Therapeutics Competitors

$0.0053
+0.00 (+35.90 %)
(As of 05/31/2019)
Add
Compare
Today's Range
$0.00
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$0.16
Volume60,300 shs
Average Volume80,439 shs
Market Capitalization$100,101.10
P/E RatioN/A
Dividend YieldN/A
Beta4.98

Competitors

Orexigen Therapeutics (OTCMKTS:OREXQ) Vs. BSPM, SKVI, STLT, PFSCF, EPRSQ, and WDBG

Should you be buying OREXQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Orexigen Therapeutics, including Biostar Pharmaceuticals (BSPM), Skinvisible (SKVI), Spotlight Innovation (STLT), ProMetic Life Sciences (PFSCF), EPIRUS Biopharmaceuticals (EPRSQ), and Woodbrook Group (WDBG).

Biostar Pharmaceuticals (OTCMKTS:BSPM) and Orexigen Therapeutics (OTCMKTS:OREXQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Risk and Volatility

Biostar Pharmaceuticals has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, Orexigen Therapeutics has a beta of 4.98, suggesting that its stock price is 398% more volatile than the S&P 500.

Profitability

This table compares Biostar Pharmaceuticals and Orexigen Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biostar PharmaceuticalsN/AN/AN/A
Orexigen TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Biostar Pharmaceuticals and Orexigen Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biostar PharmaceuticalsN/AN/AN/AN/AN/A
Orexigen Therapeutics$33.71 million0.00$-24,520,000.00N/AN/A

Biostar Pharmaceuticals has higher earnings, but lower revenue than Orexigen Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations for Biostar Pharmaceuticals and Orexigen Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biostar Pharmaceuticals0000N/A
Orexigen Therapeutics0000N/A

Summary

Orexigen Therapeutics beats Biostar Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Skinvisible (OTCMKTS:SKVI) and Orexigen Therapeutics (OTCMKTS:OREXQ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Risk & Volatility

Skinvisible has a beta of -0.44, suggesting that its share price is 144% less volatile than the S&P 500. Comparatively, Orexigen Therapeutics has a beta of 4.98, suggesting that its share price is 398% more volatile than the S&P 500.

Earnings & Valuation

This table compares Skinvisible and Orexigen Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Skinvisible$40,000.009.39$-1,700,000.00N/AN/A
Orexigen Therapeutics$33.71 million0.00$-24,520,000.00N/AN/A

Skinvisible has higher earnings, but lower revenue than Orexigen Therapeutics.

Analyst Ratings

This is a summary of recent ratings for Skinvisible and Orexigen Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Skinvisible0000N/A
Orexigen Therapeutics0000N/A

Profitability

This table compares Skinvisible and Orexigen Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Skinvisible-1,027.05%N/A-834.18%
Orexigen TherapeuticsN/AN/AN/A

Summary

Orexigen Therapeutics beats Skinvisible on 4 of the 6 factors compared between the two stocks.

Spotlight Innovation (OTCMKTS:STLT) and Orexigen Therapeutics (OTCMKTS:OREXQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Earnings and Valuation

This table compares Spotlight Innovation and Orexigen Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spotlight InnovationN/AN/AN/AN/AN/A
Orexigen Therapeutics$33.71 million0.00$-24,520,000.00N/AN/A

Spotlight Innovation has higher earnings, but lower revenue than Orexigen Therapeutics.

Profitability

This table compares Spotlight Innovation and Orexigen Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spotlight InnovationN/AN/AN/A
Orexigen TherapeuticsN/AN/AN/A

Risk and Volatility

Spotlight Innovation has a beta of -105.24, meaning that its share price is 10,624% less volatile than the S&P 500. Comparatively, Orexigen Therapeutics has a beta of 4.98, meaning that its share price is 398% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Spotlight Innovation and Orexigen Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spotlight Innovation0000N/A
Orexigen Therapeutics0000N/A

Summary

Orexigen Therapeutics beats Spotlight Innovation on 2 of the 2 factors compared between the two stocks.

ProMetic Life Sciences (OTCMKTS:PFSCF) and Orexigen Therapeutics (OTCMKTS:OREXQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Risk and Volatility

ProMetic Life Sciences has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, Orexigen Therapeutics has a beta of 4.98, meaning that its stock price is 398% more volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of ProMetic Life Sciences shares are held by institutional investors. 13.3% of Orexigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares ProMetic Life Sciences and Orexigen Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life Sciences-894.02%-3,350.55%-67.76%
Orexigen TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for ProMetic Life Sciences and Orexigen Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Orexigen Therapeutics0000N/A

Earnings & Valuation

This table compares ProMetic Life Sciences and Orexigen Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life Sciences$36.55 million3.49$-150,730,000.00N/AN/A
Orexigen Therapeutics$33.71 million0.00$-24,520,000.00N/AN/A

Orexigen Therapeutics has lower revenue, but higher earnings than ProMetic Life Sciences.

Summary

Orexigen Therapeutics beats ProMetic Life Sciences on 6 of the 9 factors compared between the two stocks.

Orexigen Therapeutics (OTCMKTS:OREXQ) and EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Valuation & Earnings

This table compares Orexigen Therapeutics and EPIRUS Biopharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orexigen Therapeutics$33.71 million0.00$-24,520,000.00N/AN/A
EPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/A

EPIRUS Biopharmaceuticals has lower revenue, but higher earnings than Orexigen Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and price targets for Orexigen Therapeutics and EPIRUS Biopharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Orexigen Therapeutics0000N/A
EPIRUS Biopharmaceuticals0000N/A

Profitability

This table compares Orexigen Therapeutics and EPIRUS Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Orexigen TherapeuticsN/AN/AN/A
EPIRUS BiopharmaceuticalsN/AN/AN/A

Risk & Volatility

Orexigen Therapeutics has a beta of 4.98, indicating that its share price is 398% more volatile than the S&P 500. Comparatively, EPIRUS Biopharmaceuticals has a beta of 6.03, indicating that its share price is 503% more volatile than the S&P 500.

Orexigen Therapeutics (OTCMKTS:OREXQ) and Woodbrook Group (OTCMKTS:WDBG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Orexigen Therapeutics and Woodbrook Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Orexigen TherapeuticsN/AN/AN/A
Woodbrook GroupN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Orexigen Therapeutics and Woodbrook Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Orexigen Therapeutics0000N/A
Woodbrook Group0000N/A

Volatility & Risk

Orexigen Therapeutics has a beta of 4.98, suggesting that its share price is 398% more volatile than the S&P 500. Comparatively, Woodbrook Group has a beta of -2.24, suggesting that its share price is 324% less volatile than the S&P 500.

Valuation & Earnings

This table compares Orexigen Therapeutics and Woodbrook Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orexigen Therapeutics$33.71 million0.00$-24,520,000.00N/AN/A
Woodbrook GroupN/AN/AN/AN/AN/A

Woodbrook Group has lower revenue, but higher earnings than Orexigen Therapeutics.

Summary

Orexigen Therapeutics beats Woodbrook Group on 2 of the 2 factors compared between the two stocks.


Orexigen Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BSPM
Biostar Pharmaceuticals
0.0$0.15+46.4%$399,000.00N/A0.00News Coverage
SKVI
Skinvisible
0.7$0.08+83.3%$376,000.00$40,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01+0.0%$343,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47+3.7%$338,000.00$36.55 million0.00Gap Up
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01+0.0%$244,000.00N/A0.00
WDBG
Woodbrook Group
0.0$1.60+0.0%$224,000.00N/A0.00
PZRXQ
PhaseRx
0.2$0.02+0.0%$185,000.00N/A0.00Gap Up
ROSGQ
Rosetta Genomics
0.0$0.08+24.2%$151,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.01+69.0%$82,000.00$20,000.000.00
AXMP
AXM Pharma
0.2$0.00+0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00+0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00+0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.01+0.0%$7,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.04+22.7%$0.00N/A0.00
Affymax logo
AFFY
Affymax
0.6$0.08+12.5%$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50+0.0%$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01+0.0%$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.01+0.0%$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07+0.0%$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01+0.0%$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49+0.0%$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04+0.0%$0.00N/A0.00
FTCY
Global Future City
0.5$0.00+0.0%$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$33.64+3.1%$0.00N/A0.00Decrease in Short Interest
News Coverage
Gap Up
HRBR
Harbor Diversified
0.0$1.12+2.7%$0.00$263.61 million0.00Gap Down
IPAH
Interpharm
0.2$0.00+0.0%$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00+0.0%$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02+8.7%$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.06+16.4%$0.00N/A0.00High Trading Volume
Gap Up
NNBP
Nanobac Pharmaceuticals
0.0$0.00+0.0%$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.06+16.0%$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02+0.0%$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00+0.0%$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.06+0.0%$0.00$26.09 million0.00
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.04+0.0%$0.00N/A0.00News Coverage
Gap Down
SYNI
Synvista Therapeutics
0.0$0.00+0.0%$0.00N/A0.00
Targeted Medical Pharma logo
TRGM
Targeted Medical Pharma
0.8$0.07+0.0%$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00+0.0%$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.02+0.0%$0.00N/A0.00
VOQP
VioQuest Pharmaceuticals
0.0$0.02+0.0%$0.00N/A0.00
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.